Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen binding site targeting CD33 (Siglec-3) on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.